SNY Live signals | Maximize Profits with Getagraph.com

SELL 2458 min ago

@ $49.08

Issued: 6 May 2024 @ 12:16

Return: 1.00%

Previous signal: May 6 - 10:35

Previous signal: Buy

Return: 0.14 %

Live Chart Being Loaded With Signals

Commentary (7 May 2024 @ 16:00):
Our systems believe the stock currently is undervalued by 0.24% compare to its pairs and should correct upwards.

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally...

Stats
Today's Volume	1.22M
Average Volume	2.08M
Market Cap	115.37B
EPS	$0 ( 2024-04-25 )
Next earnings date	( $0.890 ) 2024-07-26
Last Dividend	$1.903 ( 2023-05-30 )
Next Dividend	$0 ( N/A )
P/E	25.55
ATR14	$0.455 (0.92%)

Correlation (AI algo v.1.1b): Undervalued: 0.24% $49.69 paired level. (The Algo Track The Changes Of The Most Correlated Stocks In Realtime And Give An Instant Update)

Volume Correlation

Long: -0.56 (weak negative)

Short: -0.85 (strong negative)

Signal:(43) Neutral

Sanofi American Correlation

10 Most Positive Correlations
PPH	0.936
PWOD	0.93
ACAHU	0.925
WLFC	0.914
NWFL	0.914
EVOP	0.913
ROST	0.91
SGHT	0.909
HZNP	0.907
MGI	0.907

10 Most Negative Correlations
LNSR	-0.936
MEDS	-0.922
VS	-0.919
RMRM	-0.916
LHDX	-0.915
STRC	-0.912
TIL	-0.911
ULBI	-0.91
QLGN	-0.91
PLMR	-0.909

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Sanofi American Correlation - Currency/Commodity

-0.74
( moderate negative )

-0.41
( neutral )

0.00
( neutral )

-0.20
( neutral )

0.00
( neutral )

-0.40
( neutral )

Sanofi American Financials

Annual	2023
Revenue:	$43.07B
Gross Profit:	$26.50B (61.52 %)
EPS:	$4.31

FY	2023
Revenue:	$43.07B
Gross Profit:	$26.50B (61.52 %)
EPS:	$4.31

FY	2022
Revenue:	$45.39B
Gross Profit:	$31.70B (69.83 %)
EPS:	$6.69

FY	2021
Revenue:	$39.18B
Gross Profit:	$26.92B (68.72 %)
EPS:	$2.49

Financial Reports:

No articles found.

Sanofi American Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$3.28 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Sanofi American Dividend Information - Dividend Knight

Dividend Sustainability Score: 3.13 - low (4.25%) | Divividend Growth Potential Score: 5.64 - Stable (12.84%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.462	2003-05-28
Last Dividend	$1.903	2023-05-30
Next Dividend	$0	N/A
Payout Date	2023-06-23
Next Payout Date	N/A
# dividends	24	--
Total Paid Out	$33.25	--
Avg. Dividend % Per Year	3.34%	--
Score	3.39	--
Div. Sustainability Score	3.13
Div.Growth Potential Score	5.64
Div. Directional Score	4.39	--

Next Divdend (Est)
(2025-02-10)

$1.985 Estimate 3.15 %

Dividend Stability

0.25 Very Poor

Dividend Score

3.39

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2003	$0.462	1.49%
2004	$0.610	1.60%
2005	$0.799	2.01%
2006	$0.912	2.00%
2007	$1.145	2.48%
2008	$1.510	3.31%
2009	$1.419	4.34%
2010	$1.627	3.99%
2011	$1.822	5.55%
2012	$1.756	4.72%
2013	$1.862	3.89%
2014	$1.910	3.69%
2015	$1.618	3.55%
2016	$1.630	3.86%
2017	$1.577	3.84%
2018	$1.861	4.30%
2019	$1.739	4.06%
2020	$1.753	3.46%
2021	$1.906	3.91%
2022	$2.04	4.02%
2023	$3.28	6.69%
2024	$0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Royal	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.123	1.500	7.54	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.0961	1.500	-0.0433	-0.0649	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	6.54	1.000	8.69	8.69	[3 - 30]
operatingCashFlowPerShareTTM	8.21	2.00	7.26	10.00	[0 - 30]
freeCashFlowPerShareTTM	5.61	2.00	7.20	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.673	1.000	2.11	2.11	[0.2 - 0.8]
operatingProfitMarginTTM	0.212	1.000	7.76	7.76	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				3.13

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	16.25	1.000	8.46	0	[1 - 100]
returnOnEquityTTM	0.0961	2.50	-0.0278	-0.0649	[0.1 - 1.5]
freeCashFlowPerShareTTM	5.61	2.00	8.13	10.00	[0 - 30]
dividendYielPercentageTTM	3.87	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	8.21	2.00	7.26	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.742	1.500	8.39	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.179	1.000	8.03	0	[0.1 - 0.5]
Total Score				5.64

Sanofi American

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.